Pharmacological management of constipation

Neurogastroenterology and Motility

Volumn 21, Issue SUPPL. 2, 2009, Pages 41-54

  Emmanuel, A V ^a   Tack, J ^b   Quigley, E M ^c   Talley, N J ^d  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d MAYO CLINIC   (United States)

Author keywords

Laxatives; Opioids; Probiotics; Prokinetics; Serotonin

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ATI 7505; BISACODYL; BISOXATIN; BULKING AGENT; DOCUSATE SODIUM; HERBACEOUS AGENT; ISPAGULA; LACTULOSE; LAXAMUCIL; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MAGNESIUM HYDROXIDE; METHYLCELLULOSE; MOSAPRIDE CITRATE; NEUROTROPHIN 3; OLIGOPEPTIDE; PICOSULFATE SODIUM; POLYCARBOPHIL CALCIUM; PREBIOTIC AGENT; PROBIOTIC AGENT; PRUCALOPRIDE; PUMOSETRAG; RENZAPRIDE; SEROTONIN 4 AGONIST; TD 5108; TEGASEROD; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BRAN; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; FECES; HEADACHE; HUMAN; ILEUS; ISCHEMIC COLITIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENNA;

CONSTIPATION; GASTROINTESTINAL TRACT; HUMANS; LAXATIVES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 70350641149     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2009.01403.x     Document Type: Review

References (155)

1. Tramonte SM, Brand MB, Mulrow CD, Amato MG, O'Keefe ME, Ramirez G. The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med 1997 12 : 15 24.
2. Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001 10 : 268 273.
3. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005 100 : 936 971.
4. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003 349 : 1360 1368.
5. Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005 100 : 232 242.
6. Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective efficacy of laxatives in chronic constipation. Dig Dis Sci 2002 47 : 2222 2230.
7. Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc 1995 43 : 666 669.
8. Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 1995 9 : 639 647.
9. Fenn GC, Wilkinson PD, Lee CE, Akbar FA. A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract 1986 40 : 192 197.
10. Dettmar PW, Sykes J. A multi-centre, general practice comparison of ispaghula husk with lactulose and other laxatives in the treatment of simple constipation. Curr Med Res Opin 1998 14 : 227 233.
11. Rouse M, Chapman N, Mahapatra M, Grillage M, Atkinson SN, Prescott P. An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults. Br J Clin Pract 1991 45 : 28 30.
12. Badiali D, Corazziari E, Habib FI et al. Effect of wheat bran in treatment of chronic nonorganic constipation. A doubleblind controlled trial. Dig Dis Sci 1995 40 : 349 356.
13. Graham DY, Moser SE, Estes K. The effect of bran on bowel function in constipation. Am J Gastroenterol 1982 77 : 599 603.
14. Anderson AS, Whichelow MJ. Constipation during pregnancy: dietary fibre intake and the effect of fibre supplementation. Hum Nutr Appl Nutr 1985 39 : 202 207.
15. Hamilton JW, Wagner J, Burdick BB, Bass P. Clinical evaluation of methylcellulose as a bulk laxative. Dig Dis Sci 1988 33 : 993 998.
16. Mamtani R, Cimino JA, Kugel R, Cooperman JM. A calcium salt of an insoluble synthetic bulking laxative in elderly bedridden nursing home residents. J Am Coll Nutr 1989 8 : 554 556.
17. Hyland CM, Foran JD. Dioctyl sodium sulphosuccinate as a laxative in the elderly. Practitioner 1968 200 : 698 699.
18. Castle SC, Cantrell M, Israel DS, Samuelson MJ. Constipation prevention: empiric use of stool softeners questioned. Geriatrics 1991 46 : 84 6.
19. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998 12 : 491 497.
20. Fain AM, Susat R, Herring M, Dorton K. Treatment of constipation in geriatric and chronically ill patients: a comparison. South Med J 1978 71 : 677 680.
21. Joo JS, Ehrenpreis ED, Gonzalez L et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol 1998 26 : 283 286.
22. Xing JH, Soffer E. Adverse effects of laxatives. Dis Colon Rectum 2001 44 : 1201 1209.
23. Preziosi G, Emmanuel AV. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009 3 : 417 423.
24. MacLennan WJ, Pooler A. A comparison of sodium picosulphate ("Laxoberal") with standardised senna ("Senokot") in geriatric patients. Curr Med Res Opin 1974 2 : 641 647.
25. McCallum G, Ballinger BR, Presly AS. A trial of bran and bran biscuits for constipation in mentally handicapped and psychogeriatric patients. J Hum Nutr 1978 32 : 369 372.
26. Rider JA. Treatment of acute and chronic constipation with bisoxatin acetate and bisacodyl. Double-blind crossover study. Curr Ther Res Clin Exp 1971 13 : 386 392.
27. Szarka LA, Pemberton JH. Treatment of megacolon and megarectum. Curr Treat Options Gastroenterol 2006 9 : 343 350.
28. Bass P, Dennis S. The laxative effects of lactulose in normal and constipated subjects. J Clin Gastroenterol 1981 3 (Suppl. 1 23 28.
29. Sanders JF. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriatr Soc 1978 26 : 236 239.
30. Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE, Mimica M. Treatment of chronic constipation with lactulose syrup: results of a double-blind study. Gut 1968 9 : 84 86.
31. Andorsky RI, Goldner F. Colonic lavage solution (polyethylene glycol electrolyte lavage solution) as a treatment for chronic constipation: a double-blind, placebo-controlled study. Am J Gastroenterol 1990 85 : 261 265.
32. Corazziari E, Badiali D, Habib FI et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996 41 : 1636 1642.
33. Corazziari E, Badiali D, Bazzocchi G et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000 46 : 522 526.
34. Di Palma JA, De Ridder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000 95 : 446 450.
35. Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebocontrolled study. South Med J 2001 94 : 478 481.
36. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol 1997 37 : 904 907.
37. Attar A, Lémann M, Ferguson A et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999 44 : 226 230.
38. Rao SS, Seaton K, Miller MJ et al. Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. J Psychosom Res 2007 63 : 441 449.
39. Ashraf W, Park F, Lof J, Quigley EM. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. Am J Gastroenterol 1996 91 : 26 32.
40. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 96 : 3130 3137.
41. Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999 94 : 3530 3540.
42. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 1491.
43. US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center of Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006 4 : 79.
44. Rao SS, Mudipalli RS, Stessman M, Zimmerman B. Investigation of the utility of colorectal function tests and Rome II criteria in dyssynergic defecation (Anismus). Neurogastroenterol Motil 2004 16 : 589 596.
45. Bharucha AE, Fletcher JG. Recent advances in assessing anorectal structure and functions. Gastroenterology 2007 133 : 1069 1074.
46. Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol 2007 102 : 1964 1971. (Pubitemid 47301532)
47. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, doseranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007 25 : 1351 1361.
48. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008 103 : 170 177.
49. Johnston JM, Kurtz CB, Drossman DA et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009 104 : 125 132.
50. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999 34 : 870 877.
51. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006 10 : 209 217.
52. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005 40 : 540 551. (Pubitemid 40676247)
53. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007 64 : 1020.
54. Falk PG, Hooper LV, Mittvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 1998 62 : 1157 1170.
55. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003 361 : 512 519.
56. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002 16 : 915 931.
57. Zoppi G, Cinquetti M, Luciano A, Benini A, Muner A, Bertazzoni Minelli E. The intestinal ecosystem in chronic functional constipation. Acta Paediatr 1998 87 : 836 841.
58. Khalif IL, Konovitch EA, Maximova ID, Quigley EMM. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005 37 : 838 849.
59. O'Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol 2007 5 : 274 284.
60. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004 18 : 299 313.
61. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol 2003 38 (Suppl. 34 36.
62. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007 137 (3 Suppl. 2 830S 7S.
63. Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006 55 : 1090 1094.
64. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007 19 : 166 172.
65. Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008 Epub ahead of print.
66. Bouvier M, Meance S, Bouley C, Berta JL, Grimaud JC. Effects of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN 173 010 on colonic transit times in healthy humans. Biosci Microflora 2001 20 : 43 8.
67. Meance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001 13 : 217 222.
68. Agrawal A, Houghton LA, Morris J et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 29 : 104 114. Epub ahead of print.
69. Lesniewska V, Rowland I, Laerke HN, Grant G, Naughton PJ. Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo. Exp Physiol 2006 91 : 229 237.
70. Bouhnik Y, Neut C, Raskine L et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 2004 19 : 889 899.
71. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003 17 : 655 659.
72. Yang YX, He M, Hu G et al. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 2008 14 : 6237 6243.
73. Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebocontrolled randomized trial. J Pediatr 2005 146 : 364 369.
74. Amenta M, Cascio MT, Di Fiore P, Venturini I. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11+ FOS Actilight). Acta Biomed 2006 77 : 157 162.
75. De Paula JA, Carmuega E, Weill R. Effect of the ingestion of a symbiotic yogurt on the bowel habits of women with functional constipation. Acta Gastroenterol Latinoam 2008 38 : 16 25.
76. Bekkali NL, Bongers ME, Van den Berg MM, Liem O, Benninga MA. The role of a probiotics mixture in the treatment of childhood constipation: a pilot study. Nutr J 2007 6 : 17.
77. Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 2007 49 : 485 490.
78. Ouwehand AC, Lagstrom H, Suomalainen T, Salminen S. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002 46 : 159 162.
79. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004 38 : 475 483.
80. Pitkala KH, Strandberg TE, Finne Soveri UH, Ouwehand AC, Poussa T, Salminen S. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007 11 : 305 311.
81. Colecchia A, Vestito A, La Rocca A et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006 52 : 349 358.
82. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008 32 : 147 152.
83. Dughera L, Elia C, Navino M, Cisarò F ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed 2007 78 : 111 116.
84. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007 26 : 475 486.
85. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005 128 : 541 551.
86. Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006 101 : 326 333.
87. Baker DE. Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 2005 62 : 700 711.
88. Beattie DT, Smith JA. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008 377 : 181 203.
89. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000 95 : 2698 2709.
90. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005 39 : S184 93.
91. Buchheit KH, Buhl T. Stimulant effects of 5-hydroxytryptamine on guinea pig stomach preparations in vitro. Eur J Pharmacol 1994 262 : 91 7.
92. De Maeyer JH, Lefebvre RA, Schuurkes JA. A 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008 20 : 99 112.
93. Wagstaff AJ, Frampton JE, Croom KF. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs 2003 63 : 1101 1120.
94. Budhoo MR, Harris RP, Kellum JM. 5-Hydroxytryptamine-induced Cl- transport is mediated by 5-HT3 and 5-HT4 receptors in the rat distal colon. Eur J Pharmacol 1996 298 : 137 144.
95. Ning Y, Zhu JX, Chan HC. Regulation of ion transport by 5-hydroxytryptamine in rat colon. Clin Exp Pharmacol Physiol 2004 31 : 424 428.
96. Safsten B, Sjoblom M, Flemstrom G. Serotonin increases protective duodenal bicarbonate secretion via enteric ganglia and a 5-HT4-dependent pathway. Scand J Gastroenterol 2006 41 : 1279 1289.
97. Nguyen A, Camilleri M, Kost LJ et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997 280 : 1270 1276.
98. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998 115 : 370 380.
99. Degen L, Matzinger D, Merz M et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001 15 : 1745 1751.
100. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 468. (Pubitemid 30140843)
101. Greenwood-Van Meerveld B, Venkova K, Hicks G, Dennis E, Crowell MD. Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil 2006 18 : 76 86.
102. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003 17 : 577 585.
103. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 676.
104. Tack J, Muller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005 54 : 1707 1713.
105. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 16 : 1877 1888.
106. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 1666.
107. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007 CD003960.
108. Johanson JF, Wald A, Tougas G et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004 2 : 796 805.
109. Kamm MA, Muller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005 100 : 362 372.
110. On Chan AO, Mo Hui W, Leung G, Hu WH, Lam SK, Wong BC. Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre. Aliment Pharmacol Ther 2007 25 : 463 469.
111. Lin SR, Ke MY, Luo JY et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. World J Gastroenterol 2007 13 : 732 739.
112. Fried M, Johanson JF, Gwee KA, Wagner A, Pecher E, Rueegg P. Efficacy of tegaserod in chronic constipation in men. Am J Gastroenterol 2007 102 : 362 370.
113. American College of Gastroenterology Chronic Constipation Task Force. An evidencebased approach to the management of chronic constipation in North America. Am J Gastroenterol 2005 100 (Suppl. 1 S1 S4.
114. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998 42 : 511 516.
115. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999 288 : 93 97.
116. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999 44 : 682 686.
117. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001 120 : 354 360.
118. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002 16 : 1347 1356.
119. Sloots CE, Poen AC, Kerstens R et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002 16 : 759 767.
120. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003 67 : 82 89.
121. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 358 : 2344 2354.
122. Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche G. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 53 : 357 365.
123. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 29 : 315 328.
124. Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008 17 : 1663 1670.
125. Tack J, Middleton SJ, Horne MC et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006 23 : 1655 1665.
126. Camilleri M, McKinzie S, Fox J et al. Effect of renzapride on transit in constipation predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004 2 : 895 904.
127. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipationpredominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008 27 : 830 837.
128. Meyers NL, Hickling RI. Pharmacology and metabolism of renzapride: a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D 2008 9 : 37 63.
129. Kim HS, Choi EJ, Park H. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008 20 : 169 176.
130. Camilleri M, Manini M, McKinzie S et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 2008 20 (Suppl. 2 6 (Abstract). 131.
131. Goldberg MR, Li Y-P, Mangel AW, Johanson JF, Pitzer K, Kitt MM. In patients with chronic constipation, TD-5108, a selective 5-HT4 agonist with high intrinsic activity, relieves straining and bloating, normalizes stool consistency and reduces laxative use. Gastroenterology 2008 134 (Suppl. 1 A547. (Abstract).
132. Camilleri M, Vazquez-Roque MI, Burton D et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007 19 : 30 38.
133. Coleman NS, Marciani L, Blackshaw E et al. Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment Pharmacol Ther 2003 18 : 1039 1048.
134. Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005 30 : 611 622.
135. Buchler MW, Seiler CM, Monson JR et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008 28 : 312 325.
136. Webster L, Jansen JP, Peppin J et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008 137 : 428 440.
137. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 2001 182 : 27S 38S.
138. Foss JF, Fisher DM, Schmith VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther 2008 83 : 770 776.
139. Gonenne J, Camilleri M, Ferber I et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005 3 : 784 791.
140. Garnett W, Kelleher DL, Hickmott F et al. Alvimopan (ALV) shortens whole bowel transit time in adults with chronic constipation (CC). Gastroenterology 2004 126 : A643. (Abstract).
141. Kelleher D, Johanson J, Pobiner B, Carter E, Dukes G. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist - a study in patients with chronic idiopathic constipation (CIC) not taking opioid medication. Am J Gastroenterol 2006 101 : S480. (Abstract).
142. Russell J, Bass P, Goldberg LI, Schuster CR, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982 78 : 255 261.
143. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985 24 : 181 191.
144. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008 358 : 2332 2343.
145. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000 283 : 367 372.
146. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996 59 : 469 475.
147. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997 87 : 765 770.
148. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997 61 : 467 475.
149. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioidinduced bowel dysfunction. Cochrane Database Syst Rev 2008 CD006332.
150. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006 290 : G942 7.
151. Sweetser S, Busciglio IA, Camilleri M et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009 296 : G295 301.
152. Andresen V, Camilleri M, Busciglio IA et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007 33 : 61 8.
153. Johnston J, MacDougall J, Lavins B et al. Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: results from a large twelve-week, randomized, double-blind, placebocontrolled study. Am J Gastroenterol 2008 103 : S460 1. (Abstract).
154. Coulie B, Szarka LA, Camilleri M et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000 119 : 41 50.
155. Parkman HP, Rao SS, Reynolds JC et al. Functional Constipation Study Investigators. Neurotrophin-3 improves functional constipation. Am J Gastroenterol 2003 98 : 1338 1347.